Amryt, the pharmaceutical company focused on treatments for rare and orphan diseases, has appointed David Allmond as Chief Commercial Officer in a non-board capacity, with effect from 3 April 2017.
Allmond has joined the Company from Aegerion Pharmaceuticals where he was President of EMEA and, in particular, involved in the commercialization of Lojuxta (lomitapide), the drug used to treat Homozygous Familial Hypercholesterolemia (HoFH). Amryt acquired the exclusive rights to sell Lojuxta across the EU and MENA in December 2016.
The new CCO will succeed Michele Bellandi who has left the Company and effected a smooth handover, the company said.
Joe Wiley, CEO of Amryt, said that Allmond will resume control of the Lojuxta team and announced potential opening of new markets.
Wiley also said that Allmond will take responsibility for the launch preparation for AP101:
“As recently announced we have obtained regulatory clarity from the FDA and EMA regarding the design of our single pivotal Phase 3 clinical trial for AP101 as a potential treatment for Epidermolysis Bullosa (“EB”). We are currently on track to commence this study at the end of March.”